News

U.S. court lets Grifols sue Gotham City for defamation over short report, but dismisses most claims in major financial free ...
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company ...
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...
Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...
Under this collaboration, XL-protein will leverage its proprietary, clinical-stage PASylation ® technology to extend the circulation of Grifols therapeutics, paving the way for a more effective and ...
Grifols, S.A. (NASDAQ:GRFS) is a company that unfortunately has not been performing as I expected it to. My position is in the green, but this has more to do with FX and me adding shares below my ...
Privately-owned German biotech XL-protein GmbH today announced that it has entered into a worldwide license, development and ...
Grifols GRF-0.39%decrease; red down pointing triangle said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks for a 6.45 billion-euro ...
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.
Spanish drugmaker Grifols SA, the target of a short-seller attack earlier in the year, is seeking to hire an external consultancy firm to help deal with minority investors as it faces a takeover ...
Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the Spanish drugmaker at €6.45 billion ($6.8 billion). The offer ...
Below, we take a look at Grifols (GRFS), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings ...